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ABSTRACT
Background: The prognosis of patients with hepatocellular carcinoma (HCC) 
undergoing transarterial chemoembolization (TACE) is variable, despite a myriad of 
prognostic markers. We compared and integrated the established prognostic models, 
HAP and ART scores, for their accuracy of overall survival (OS) prediction.
Results: In both training and validation sets, HAP and ART scores emerged as 
independent predictors of OS (p<0.01) with HAP achieving better prognostic accuracy 
(c-index: 0.68) over ART (0.57). We tested both scores in combination to evaluate 
their combined ability to predict OS. Subgroup analysis of BCLC-C patients revealed 
favorable HAP stage (p<0.001) and radiological response after initial TACE (p<0.001) 
as positive prognostic factors.
Patients and Methods: Prognostic scores were studied using multivariable Cox 
regression and c-index analysis in 83 subjects with Barcelona Clinic Liver Cancer 
(BCLC) A/B stage from UK and Italy (training set), and 660 from Korea and Japan 
(validation set), all treated with conventional TACE. Scores were further validated in 
an separate analysis of patients with BCLC-C stage disease (n=63) receiving initial 
TACE.
Conclusion: ART and HAP scores are validated indices in patients with 
intermediate stage HCC undergoing TACE. The HAP score is best suited for screening 
patients prior to initial TACE, whilst sequential ART assessment improves early 
detection of chemoembolization failure. BCLC-C patients with low HAP stage may be 
a subgroup where TACE should be explored in clinical studies.
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INTRODUCTION
Patients presenting with liver-confined 
hepatocellular carcinoma (HCC), preserved liver function 
and performance status cluster into “intermediate stage” 
or Barcelona Clinic Liver Cancer (BCLC) B category 
[1]. In this patient subgroup where overall survival (OS) 
often extends beyond 2 years [2], guidelines recommend 
trans-arterial chemoembolization (TACE) with the intent 
of prolonging OS by achieving local disease control [3].
TACE is also indicated in early HCC when surgery 
or radiofrequency ablation is contraindicated [4]. In 
parallel, whilst not supported by randomized controlled 
trials (RCT), a growing number of single-center studies 
indicate that embolization is safe and effective also in 
patients with segmental portal vein invasion or systemic 
metastases [5]. Because of the evolving experience 
in the administration of TACE, achieving consensus 
regarding optimal selection criteria and best re-treatment 
strategy is critical in improving and maintaining clinical 
outcomes [6].
However, due to the heterogeneity in the prognosis 
of BCLC-B HCC, where predicted OS ranges from 11 to 
45 months, treatment decisions in the individual patient 
are partially subjective, being influenced by the local 
expertise within each institution [7]. Previous studies 
have identified a number of individual adverse prognostic 
traits in patients undergoing TACE [8]. These have been 
variously combined to derive coherent prognostic models 
aiming to standardize the prognostic assessment across 
institutions [7, 9–12]. Based on these scores, subjects with 
shorter survival expectancy might be offered systemic 
treatment or best supportive care, avoiding exposure to 
the adverse effects of TACE.
Of the prognostic scores, the hepatoma arterial-
embolization prognostic (HAP) score is a model 
constructed on baseline pre-TACE hypoalbuminemia <35 
g/L, bilirubin >17 mmol/L, AFP >400 ng/ml and tumor 
size >7 cm designed to guide initial TACE treatment [11]. 
A second, recently qualified prognostic model, the ART 
score, is based on the deterioration of liver biochemistry 
following initial TACE and the presence of radiological 
response to treatment [12], and can be used to identify 
patients who may benefit from sequential retreatment [13] 
(Table 1).
Whilst scientifically interesting, the relationship 
between these scores and patient’s overall survival has 
been questioned following validation in independent 
cohorts, casting doubt upon their clinical utility [14, 15]. 
As a result, the use of either score is not advocated within 
the current management guidelines for HCC. In addition, 
there are no available data to suggest which score is best in 
predicting patient prognosis, or how best to combine both 
scores in the clinical setting.
We designed this multi-institutional study aiming to 
validate the accuracy of HAP and ART score in predicting 
patients’ survival after initial TACE. We employed 
independent cohorts of unselected, consecutive patients 
with HCC presenting within intermediate stage criteria 
from Europe and Asia to ensure ample generalizability 
of the results, evaluating both scores individually and 
in combination. Secondarily, we intended to investigate 
whether the proposed scores preserved prognostic 
prediction in a subgroup of patients exceeding BCLC-B 
criteria treated with TACE in a post-hoc analysis.
RESULTS
Demographics
The clinicopathologic features of both datasets are 
illustrated in Table 2. In the training set, median age was 
72 years, 50% of the patients were staged as intermediate 
stage HCC according the BCLC algorithm, with preserved 
liver function (CTP A, 75%). Minimum follow-up time 
was 4 months or until date of death. At the time of analysis 
37% of patients had died. Median OS was 26 months (4-
162 months).
Survival analysis
On univariable analyses, intrahepatic spread 
(p<0.007), tumor size >5cm (p<0.001), AFP>400 ng/ml 
(p<0.001), CTP class (p=0.008), radiologic response post-
TACE (p=0.002), CLIP (p<0.001), HAP (p<0.001) and 
ART score (p=0.002) emerged as significant predictors 
of OS in the training set (Table 3). Based on ART score, 
the median OS for patients of good prognosis (ART score 
<2.5) was 55 months, reducing to 22 months in patients 
with a poor score (Figure 2A). In patients with HAP 
stage A disease, median OS was not reached at the end 
of observation. Patients within HAP stage B or C had a 
median OS of 55 and 46 months respectively, deteriorating 
to 9 months in stage D disease (Figure 2B).
A multivariable regression model was constructed 
including HAP, ART score, mRECIST and CLIP score 
(categorized as 0-1 versus >2) with other significant 
univariable predictors being excluded from analysis to 
avoid collinearity. Cox regression analysis confirmed 
HAP and ART scores (Supplementary Table 1) together 
with mRECIST (Hazard Ratio [HR] 1.5 95%CI 1.0-2.3, 
p=0.04) as independent predictors of patients’ OS.
Validation of prognostic models
The prognostic accuracy of the ART and HAP scores 
was further tested in a larger, independent validation 
dataset. As shown in Table 2, there was homogeneity 
across both datasets in terms of age, gender distribution, 
liver functional reserve (CTP A, 75%), stage (BCLC-B, 
60%) and median OS which in the validation set, 23 
months (range 1-115 months).
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Table 2: Demographic and clinical characteristics of patients with HCC treated with TACE (training and validation 
set)
Baseline characteristic n=83, (%) or median, (range) n=660, (%) or median, 
(range)
Age, years 72 (47-84) 73 (42-89)
Gender
Male
Female
64 (77)
19 (23)
465 (70)
195 (30)
Aetiology of Chronic Liver Disease
Viral
Non Viral
Not characterized
49 (60)
31 (37)
3 (3)
533 (80)
127 (20)
Child Turcotte Pugh Class
A5
A6
B7
B8
B9
37 (45)
25 (30)
14 (17)
5 (6)
2 (2)
332 (49)
168 (26)
94 (14)
43 (7)
23 (4)
Maximum tumour diameter
< 5 cm
> 5 cm
26 (40)
38 (60)
565 (86)
95 (14)
Number of nodules
1
2
3
>3
Missing
28 (34)
22 (26)
16 (20)
17 (20)
-
110 (17)
120 (18)
97 (15)
248 (38)
85 (12)
AFP
<400 ng/mL
>400 ng/mL
77 (93)
6 (7)
534 (81)
126 (19)
Albumin, g/L 37 (23-49) 37 (20-50)
Total bilirubin, umol/L 19 (7-55) 14 (3-70)
ALT, IU/L 48 (13-177) 37 (4-277)
AST, IU/L 56 (16-188) 48 (6-303)
Table 1: The hepatoma arterial-embolisation prognostic (HAP) score and the assessment for re-treatment with 
TACE (ART) score
Prognostic Model Variables Prognostic Stratification
HAP Score
Albumin <35 g/L
AFP >400 ng/dL
Tumor diameter >7cm
Bilirubin >17mmol/L
HAP A
HAP B
HAP C
HAP D
ART Score
Child Pugh increase following TACE (+1, +2 points)
AST >25% from baseline
Lack of radiologic response
High risk (>2.5)
Low risk (<2.5)
(Continued )
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Both ART and HAP score remained significant on 
univariate (p<0.001) and multivariate (p<0.001) analysis 
of OS with adjusted hazard ratios shown in Supplementary 
Table 2. Patients with an ART score >2.5 after initial 
TACE had an OS of 29 months (range 23-34) compared 
to those with an ART score <2.5 whose median OS was 
45 months (range 40-50, p<0.001) (Figure 2C). Patients 
within HAP stage A or B had median OS of 52 (95%CI 
45-58) and 37 (30-44) months compared with stage C or 
D with median OS of 19 (14-25) and 9 (8-10) months, 
respectively (p<0.001) (Figure 2D). Radiologic response 
to treatment emerged as additional multivariable predictor 
of OS (HR 1.7 95%CI 1.6-1.8 p<0.001).
We assessed the accuracy of the HAP and ART score 
in predicting early mortality using ROC curve analysis 
based on 1 and 2-year survival rates. In the training 
set, both scores had acceptable accuracy in estimating 
mortality after initial TACE, with AUROC values of 0.67 
(95%CI 0.50-0-85) for the ART score and 0.75 (95%CI 
0.62-0.89) for the HAP score at 1 year, and 0.75 (95%CI 
0.63-0.86) for the ART score and 0.73 (95%CI 0.62-0-85) 
for the HAP score at 2 years (p<0.05) (Supplementary 
Figure 1A-B). In the validation set, the HAP score was a 
more accurate predictor of 1-year mortality with AUROC 
values of 0.70 (95%CI 0.66-0.75) compared to the ART 
score 0.57 (95%CI 0.52-0.62, p<0.05). Similarly, 2-year 
Baseline characteristic n=83, (%) or median, (range) n=660, (%) or median, 
(range)
ALP, IU/L 255 (113-529) 336 (108-1212)
INR 1.2 (1.0-1.6) 1.0 (1.0-2.0)
Platelet Count, x 109/L 115 (26-269) 115 (14-453)
BCLC Stage
A
B
42 (50)
41 (50)
270 (40)
390 (60)
CLIP Score
0-1
>2
61 (73)
22 (27)
N.A.
Number of TACE procedures
1
2
>3
Missing
42 (50)
16 (20)
25 (30)
-
171 (26)
139 (21)
274 (42)
76 (11)
Prior Treatments
First line TACE
Resection
Transplantation
Radiofrequency ablation
Systemic treatment
50 (60)
6 (7)
1 (1)
22 (27)
4 (3)
322 (48)
77 (12)
0 (0)
243 (36)
18 (4)
Modified RECIST response following 
TACE
Complete Response
Partial Response
Stable Disease
Progressive Disease
22 (26)
40 (48)
12 (15)
9 (11)
268 (40)
110 (17)
91 (14)
191 (29)
HAP Score
A
B
C
D
23 (28)
32 (39)
24 (30)
3 (3)
274 (41)
209 (32)
137 (21)
40 (6)
ART Score
<2.5
>2.5
55 (66)
28 (44)
423 (64)
237 (36)
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mortality was more accurately predicted by the HAP score 
(0.67, 95%CI 0.63-0.71) than the ART score (0.53, 95%CI 
0.50-0.58, p<0.05) (Supplementary Figure 1C-D).
The discriminatory capacity of each prognostic 
system was compared by means of Harrell’s concordance 
index [22]. The HAP score displayed an overall better 
discriminatory ability in predicting OS with a c-score 
of 0.68 (95%CI 0.64-0.70) compared to the ART score 
(c-score 0.57, 95%CI 0.53- 0.60). The combination of 
Table 3: Univariate analysis of prognostic factors of overall survival (training set)
UNIVARIATE ANALYSIS
Variable N=83 Median OS (95% CI) Hazard Ratio (95% 
CI)
P-value
Age
<65
>65
32
51 - - 0.45
Etiology
Viral
Non-viral
31
49
- - 0.91
Intrahepatic spread
Uninodular <50%
Multinodular <50%
Massive >50%
27
51
8
104 (12-196)
50 (40-59)
19 (5-35)
2.6 (1.3 – 5.2) 0.007*
Maximum tumour 
diameter
<5 cm
>5 cm
67
20
55 (20-90)
21 (16-27)
3.9 (1.7-8.7) <0.001*
AFP, ng/ml
<400
>400
78
8
55 (17-93)
14 (7-21)
8.2 (3.3 – 20.8) <0.001*
CLIP Score*
0-1
>2
61
22
104 (32-176)
22 (18-25)
2.3 (1.5-2.5) 0.001*
BCLC
A
B
42
41
- - 0.22
Child Turcotte Pugh 
Class
A
B
62
21
104 (33-175)
46 (10-83)
2.9 (1.3-6.5) 0.008*
Tumour Response 
(mRECIST)
CR
PR
SD
PD
22
40
12
9
NR
55 (36-73)
52 (26-79)
21 (7-37)
1.9 (1.2-2.9) 0.002*
HAP Score
A
B
C
D
23
32
24
3
NR
55 (34-75)
46 (18-82)
9 (43-63)
3.1 (1.8-5.3) <0.001*
ART Score
<2.5
>2.5
55
28
104 (30-160)
22 (10-47)
3.1 (1.5-6.7) 0.002*
NR: Not reached.
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Figure 2: Kaplan Meier curve analysis showing the effect of ART and HAP score as predictors of overall survival in HCC in the training 
(A, B) and in the validation set (C, D).
HAP and ART score yielded a pooled c-score of 0.69 (95% 
CI 0.65-0.72).
We further confirmed the prognostic validity of 
both HAP and ART score in a pooled analysis of patients 
belonging to both training and validation sets (n=746). 
As shown in Supplementary Figure 2, this confirmed 
the prognostic value of both scores in the entire study 
population (Log rank p<0.001 for both HAP and ART 
scores). Given the independent prognostic role observed 
for the HAP and ART scores we evaluated the accuracy 
of their combined sequential use in the entire study 
population. As shown in Supplementary Table 3, the ART 
score was able to detect a significant survival difference 
of 15 months in HAP B (p<0.001), 17.1 months in HAP C 
(p=0.001) and 1 month in HAP D (p=0.02) patients, with 
no effect on survival seen for patients clustering in HAP A 
stage (p=0.96) (Supplementary Figure 3).
Evaluation of prognostic models in patients 
exceeding BCLC-B criteria
We performed a separate survival analysis on 63 
patients derived from the validation set who had been 
offered TACE despite exceeding BCLC-B staging criteria 
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due to visceral metastatic spread (n=29, 46%), segmental 
portal vein involvement (n=34, 54%) or Child C cirrhosis 
(n=1, 1%). These patients had been excluded from the 
principal analysis (Figure 1). The median survival of this 
patient subgroup was 11.8 months (range 1.4-59 months) 
with a total of 45 deaths (71%) at the time of data analysis. 
Full clinicopathologic characterization is provided in 
Table 4.
Survival analysis revealed that response to TACE 
(HR 2.0 1.4-2.8, p<0.001) and the HAP (p=0.02) but not 
the ART score (p=0.39) predict OS after initial TACE. 
Median OS was 25.9 (range 8.6-43.1) in HAP A stage, 
23.3 months (range 19.0-27.6) in HAP stage B, 11.8 
months (5.4-11.8) in stage C and 10 months (6.5-13.4) in 
stage D (HR 1.5, 95%CI 1.1-2.2, p=0.02). However, in 
patients with BCLC-C, OS was not significantly different 
across HAP stages A and B (p=0.75), nor across C and D 
(p=0.06). The accuracy of OS estimation was optimized 
by dichotomizing the HAP score into stages A+B (median 
OS 23 months, range 12-34 months) against C+D (median 
OS 10 months, range 5-14 months, HR 2.6 95%CI 1.4-
4.9 p=0.002). According to mRECIST criteria, median 
OS was 8 months (range 6-11 months) in patients with 
progressive disease, 16 months (range 8-25 months) with 
stable disease and 26 months with complete and partial 
response (range 6-45 months, p<0.001)(Figure 3).
DISCUSSION
The use of TACE in unresectable HCC as a 
palliative measure to improve survival whilst maintaining 
quality of life is supported by level I evidence from 
2 primary RCTs and 3 meta-analyses [3]. However, 
significant heterogeneity in median OS has been reported 
in patients receiving TACE, varying from 16-40 months 
in early stage disease to 15-27 months in intermediate 
[23] and 4-15 months in advanced disease [5]. The wide 
range in OS figures observed within each stage stems from 
inter-institution variability in patient selection, diverse re-
treatment criteria, and the evolving technique in delivering 
TACE.
Given the palliative intent of TACE it is important 
that patient selection is not only driven by the technical 
feasibility of the procedure, but also guided by careful 
consideration of the potential survival benefit against the 
risk of post-procedural adverse events. For this reason, the 
Figure 1: Study flow diagram illustrating patient inclusion in the training and validation set.
Oncotarget8www.impactjournals.com/oncotarget
Table 4: Clinicopathologic characteristics of patients exceeding BCLC-B criteria
Baseline characteristic n=63, (%) or median, (range)
Age, years 53 (34-87)
Gender
Male
Female
48 (76)
15 (24)
Aetiology of Chronic Liver Disease
Viral
Non Viral
48 (76)
15 (24)
Child Turcotte Pugh Class
A
B
C
51 (80)
11 (19)
1 (1)
Maximum tumour diameter
< 5 cm
> 5 cm
33 (52)
30 (48)
Number of nodules
1
2
>3
5 (8)
15 (24)
43 (68)
Extrahepatic Metastasis
Absent
Present
34 (54)
29 (46)
Portal Vein Involvement (segmental)
Absent
Present
29 (46)
34 (54)
AFP
<400 ng/mL
>400 ng/mL
43 (68)
20 (32)
Albumin, g/L 37 (21-46)
Total bilirubin, umol/L 13 (3-53)
ALT, IU/L 44 (10-122)
AST, IU/L 56 (14-138)
ALP, IU/L 220 (120-1901)
INR 1.1 (1.0-1.6)
Platelet Count, x 109/L 121 (14-1653)
Number of TACE procedures
1
2
>3
31 (50)
17 (20)
15 (30)
Modified RECIST response following TACE
Complete Response
Partial Response
Stable Disease
Progressive Disease
3 (5)
21 (32)
11 (18)
28 (45)
HAP Score
A
B
C
D
12 (19)
20 (32)
22 (35)
9 (14)
ART Score
<2.5
>2.5
32 (51)
31 (49)
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development of biomarkers to allow for a more objective 
selection of TACE candidates based on the likelihood to 
benefit from treatment has been at the focus of intense 
research efforts.
In our multi-institutional retrospective study of 
prognostic factors, the largest to our knowledge, we 
validated for the first time the significance of two recently 
qualified models, the HAP and the ART score in both 
Western and Asian patient populations, where survival 
outcomes can significantly differ as a result of the diverse 
disease etiology, screening policy and subsequent clinical 
management [24]. These scores have been proposed 
as objective and mutually exclusive strategies to select 
patients for initial as well as subsequent loco-regional 
therapies based on their capacity to predict long-term 
survival following TACE. Their prognostic potential, 
however, has never been compared, a point of major 
consequence given the emergence of discrepancies from 
their independent evaluation in separate studies, which has 
lead to uncertainties in terms of which strategy should be 
prioritized for clinical use [14, 15].
Whilst meant to inform treatment decisions in 
intermediate stage HCC, the original study that qualified 
the HAP score included only 31% of the patients with 
BCLC-B stage, with lack of complete staging data in the 
validation set. In addition, 36% of the patients exceeded 
BCLC-B criteria, though variables including portal 
vein involvement, PS or extra-hepatic disease were not 
(Continued )
Figure 3: Kaplan Meier curve analysis showing the effect of different prognostic models on the overall survival of a subgroup of patients 
exceeding intermediate HCC staging criteria: ART score (A), HAP score (B, C) mRECIST based radiologic response (D). 
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documented in the analysis, potentially causing a greater 
heterogeneity in survival [11].
Similar pitfalls may influence the validity of the 
ART score, where recent retrospective studies have 
in fact demonstrated that only 10-15% of the patients 
were eligible for ART score testing [14, 15] based on 
the original eligibility criteria, which excluded patients 
<2 TACE within 90 days [12], suggesting a reduced 
applicability of the model in the general population.
Unlike other studies, we included TACE candidates 
consecutively and in an unselected manner apart from 
BCLC stage, therefore allowing for the prognostic scores 
to predict for outcome after initial TACE more closely to 
a “real life” clinical practice scenario. In our study, both 
scores emerged as highly significant predictors of OS 
(Figure 2), preserving an independent effect when tested 
on a multivariable Cox regression model (Supplementary 
Tables 1, 2). Our data show that the HAP score displayed 
better accuracy in estimating short-term mortality at 1 
and 2 years following TACE (Supplementary Figure 1), a 
finding that was confirmed by c-index analysis indicating 
a superior predictive accuracy of the HAP over the ART 
score in estimating long term OS.
Interestingly, whilst the predicted survival for each 
HAP stage in this study was similar to that of previously 
published data [11], wider OS differences were observed 
in the poor prognostic group according to the ART score 
(22 and 29 months in our study; 6.6 and 8.1 months in 
the study by Sieghart et al. [12]). There are several 
reasons that may account for the survival differences 
observed. Firstly, our study includes a significantly 
higher proportion of BCLC-A in both datasets. The ART 
score was derived from dynamic changes in biochemical 
and radiological parameters following initial TACE, 
and patients with <2 TACE within 90 days and those 
achieving complete response after initial treatment were 
excluded in the original study. Equally, survival times 
were calculated from the day of the second TACE, and 
reassessment of liver function was carried out one day 
prior to second TACE [12]. The different purpose of 
Figure 3(Continued ): Panel E illustrates a proposed algorithm for the sequential use of the HAP and ART score in BCLC-A/B stage 
patients.
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our study, however, required a standardized comparison 
in homogenous populations unselected for clinico-
pathologic features other than BCLC stage. This is 
a key point in the prognostic evaluation of the ART 
score, whose prognostic ability has been questioned in a 
previous analysis published by Kudo et al. which included 
patients from the same cohort included in this study [14]. 
The different selection criteria used for the two studies, 
however, are important in explaining the difference in our 
results. In the analysis by Kudo and in a subsequent, more 
comprehensive evaluation of the ART score in a cohort of 
988 patients [25], only 12% of the patients underwent ≥2 
TACE sessions within 90 days. In these patients the ART 
score failed to predict prognosis.
In our study, we obtained repeat blood tests and 
concurrent imaging reassessment 6-8 weeks after initial 
TACE, when patients presented for consideration of 
retreatment, a setting that – we believe – replicates a 
more appropriate time point for the clinical application of 
the ART score, rather than a pre-planned second TACE 
[12]. We also did not apply the 90-days interval criteria, 
considering the prognostic performance of the score in the 
whole patient population. Whilst the inherent differences 
in study design may account, in our opinion, for the 
heterogeneity in survival observed in ART score strata 
across studies, it should be emphasized that our study 
better approximates a routine clinical practice scenario 
where changes in the ART score could prompt changes in 
the management of unselected patients assessed following 
initial TACE. Whilst holding the undoubted advantage to 
be used sequentially to guide retreatment beyond initial 
TACE [10], based on our data, the ART score calculated 
after first TACE holds inferior accuracy in predicting short 
and long term prognosis compared to the HAP score.
However, given that both scores maintained a 
strong and independent prognostic value in our study, 
we were interested in testing their integrated effect in 
predicting OS in a large pooled cohort of 746 cases 
satisfying intermediate stage criteria. As shown in 
Supplementary Table 3, whilst the addition of the ART 
score is minimally or not significant at the extreme 
stages of the HAP prognostic algorithm, we surprisingly 
demonstrate the highest levels significance in the 
integration of the ART score in patients who belong 
to HAP stages B and C, suggesting that the dynamic 
changes in liver function and radiologic progression 
which compose the ART score may aid clinicians to 
reduce disease and treatment-related heterogeneity in 
survival outcomes, allowing to identify patients who are 
at higher risk of early mortality.
We propose an integrated algorithm with 
sequential use of both indices that may further refine 
prognostic prediction, with the HAP score being used as 
a screening tool to identify optimal candidates for initial 
TACE and the ART being sequentially used to identify 
early chemoembolization failure (Figure 3E). Whilst 
provocative, these conclusions should be further explored 
in adequately powered prospective studies.
As a secondary aim, we explored the prognostic 
in a separate analysis of a subgroup of patients with 
BCLC-C HCC, a patient subpopulation where TACE 
has been delivered with smaller but yet significant 
survival benefit in a number of retrospective case series 
[5]. Whilst the decision to treat was not supported by 
current BCLC guidelines, these patients received TACE 
at the discretion of the treating multidiscipilnary team, 
who felt, following case-by-case review, that TACE 
could have resulted in higher chances to achieve tumor 
control compared to other available therapies. We have 
shown that patients in the lower risk HAP stages, and 
those responding to initial TACE, achieve significant 
long-term benefit from treatment, albeit less than that 
in stage BCLC A/B. Interestingly, the ART score was 
not prognostic. Whilst the provision of TACE outside 
BCLC B stage should not be encouraged due to the 
lack of level I evidence, our findings are provocative in 
suggesting that a subset of patients with BCLC-C and 
HAP stage A+B, may benefit from TACE, a finding that 
may instigate further research.
The retrospective design and the relatively 
limited size of the training cohort stand as noteworthy 
limitations to our study. Perhaps unsurprisingly, the two 
cohorts demonstrated significant clinical heterogeneity, 
with Asian patients displaying lower tumor burden 
compared to Europeans, as a likely result of differing 
adherence to screening policies [14]. However, the 
process of independent validation in a large, independent 
cohort, the largest to have been utilized so far for 
the evaluation of prognostic models in intermediate-
stage HCC, in conjunction with the levels of statistical 
significance achieved, confirms the validity, accuracy and 
generalizability of our results.
Additionally, we have analyzed objective and 
routinely collected data, which are likely to provide 
very low recall bias. The proportion of BCLC-A patients 
in both cohorts, who were offered TACE following 
multidisciplinary discussion confirming patient 
unsuitability for radical treatments, may account for the 
better survival figures observed here compared to other 
studies. Their inclusion is important in testing prognostic 
models in unselected TACE candidates. However, the 
significantly wider survival of this patient subgroup [26] 
warrants further validation studies focusing specifically on 
BCLC-A stage disease.
It is interesting to note that ROC curve analysis 
revealed AUROC values <0.75 in the prediction of 
landmark survival endpoints at 1 and 2 years, a finding 
that highlights the need to research into other factors other 
than those considered in the tested prognostic models 
as determinants of patients’ survival after initial TACE. 
Similar considerations stem from the appraisal of the 
combined predictive ability of the combination of HAP 
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and ART score, where Harrel’s c index analysis produced 
an overall score of 0.69.
In summary, we have demonstrated the HAP score 
as an accurate predictor of short and long-term mortality, 
advocating a better-suited role in the initial screening of 
TACE candidates. We propose the use of the ART score, 
a more effective model for sequential risk-assessment, to 
assess suitability of patients prior to retreatment following 
initial TACE. We showed the potential for both scores to 
integrate in a uniform, objective and readily applicable 
selection strategy to optimize the provision of TACE in 
patients within intermediate-stage criteria, highlighting 
limitations within BCLC-A and C stage tumours.
Our study provides preliminary but stimulating 
evidence regarding the use of TACE in advanced disease, 
suggesting a potential benefit in a subgroup of patients 
with good HAP stage. Whilst thought provoking, our 
findings stem from a limited sample size, predominantly 
from a single-institution, and warrant verification in 
independent, adequately powered studies, especially given 
the role of the provision of further anticancer therapies 
post-TACE refractoriness in influencing patients’ survival. 
Equally, the exclusion of patients with incomplete data 
might have lead to selection bias, an issue that further 
strengthens the need for prospective validation of our 
findings.
As the number of prognostic models is increasing 
rapidly based on retrospective evidence [27–30], further 
prospective clinical trials should be instigated to confirm 
the clinical utility of the proposed prognostic biomarkers 
in the management of intermediate stage HCC.
PATIENTS AND METHODS
Patient characteristics
Our training set population was retrospectively 
collected and consisted of a total of 83 subjects including 
58 consecutive patients treated with TACE between 2004 
and 2013 at the academic Liver Unit in Novara (Italy), 
and patients eligible for the assessment of the ART score 
(n=25) obtained from a larger database of 64 consecutive 
patients treated at the Hammersmith Hospital, Imperial 
College London (UK) between 2001 and 2012. Patients 
exceeding BCLC-B criteria, i.e. with segmental portal 
vein thrombosis (n=4) or Child C cirrhosis (n=5) were 
excluded from the primary analysis (Figure 1).
The diagnosis of HCC was made according to the 
American Association for the Study of the Liver criteria 
[16]. Patients demographics, full blood count, liver 
function tests, AFP, tumor staging, Child-Turcotte-Pugh 
(CTP) class, Barcelona Clinic Liver Cancer (BCLC) [1] 
and Cancer of the Liver Italian Program (CLIP) [17] 
scores were collected prior to treatment. All patients had 
a performance status of zero. OS was calculated from the 
time of the first TACE to the time of death or last clinical 
follow up. Calculation of the HAP score followed the 
criteria published by Kadalayil et al [11]. Calculation 
of the ART score followed previously published criteria 
[12]: both biochemical and radiologic parameters were 
obtained 6-8 weeks following initial TACE. Multiphase 
contrast-enhanced computed tomography (CT) images 
were reported by a senior radiologist blinded to survival 
data in accordance with modified Response Evaluation 
in Solid Tumors (mRECIST) criteria [18]. At both 
institutions TACE protocol was planned following 
multidisciplinary review of clinical data and staging 
CT and confirmed on pre-treatment hepatic arterial 
angiogram. Depending on tumour burden and vascular 
anatomy, TACE was administered selectively or super-
selectively using a 2.7-2.8 Fr microcathether, which 
served for intrarterial infusion of doxorubicin emulsified 
in lipiodol followed by embolization with gelatin 
sponge particles: in total. TACE was super-selective 
in a total of 49 patients (59%), selective in 28 (34%) 
whereas 6 patients (7%) had lobar TACE. Following 
TACE-refractoriness a total of 28 patients received 
sorafenib after TACE refractoriness (34%), whilst 6 had 
radiofrequency ablation of the residual disease (7%) and 
2 had surgical resection (2%). All the remaining patients 
received best supportive care only.
For the purpose of this study we defined TACE 
refractoriness as a pattern of disease progression that 
would prevent safe and effective treatment with repeat 
TACE. This included the emergence of extrahepatic 
disease progression, multifocal intrahepatic disease 
progression no longer amenable to TACE or loss of 
adequate arterial vascular access feeding the residual 
viable disease.
Validation of prognostic scores
The validation dataset was constructed as shown 
in Figure 1. This included a prospective series of 79 
cases of HCC diagnosed at St. Mary’s Hospital, Catholic 
University of Korea (Seoul, Republic of Korea) between 
June 2011 and July 2012 and a second retrospectively 
collected dataset of 644 consecutive patients with 
unresectable HCC treated with TACE at the Kinki 
University Faculty of Medicine (Osaka, Japan) between 
January 2004 and August 2013. In the Japanese subgroup 
chemoembolization was performed using 20-50 mg of 
epirubicin or 50-100 mg of cisplatin emulsified with 
lipiodol and gelatin sponge particles, for the Korean 
patients the TACE protocol consisted in the infusion of 
doxorubicin (50 mg) or combined epirubicin (50 mg) 
and cisplatin (60 mg) in a mixture of lipiodol followed 
by gelatin sponge embolization. Patients received intra-
arterial treatment as appropriate for tumour burden, 
similarly to the training set. In total 572 patients (80%) 
had selective TACE, whilst the remaining 151 (20%) had 
lobar TACE. Response to treatment by mRECIST criteria 
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was assessed 6-8 weeks after TACE, reported by a senior 
radiologist blinded to survival data.
Treatment data post-TACE refractoriness was 
collected. In the Korean sub-cohort, patients were 
accrued prior to the clinical availability of sorafenib and 
were treated with hepatic intra-arterial chemotherapy 
(HAIC) with epirubicin (50 mg) and cisplatin (60 mg) as 
previously described [19]. In the Japanese group, HAIC 
or systemic treatment with sorafenib or TS-1 were offered 
in patients displaying progressive disease no longer 
amenable to TACE. In total, 145 patients (20%) receive 
HAIC, whilst 148 (20%) were offered sorafenib and 33 
(5%) receved TS-1, whilst the remaining patients received 
best supportive care only. The study was approved by 
the local Research Ethics Committees and conducted in 
accordance to the principles of the Declaration of Helsinki. 
All institutions used a “treatment on demand” TACE 
schedule and no TACE was delivered in the presence of 
complete radiologic response.
Statistical analysis
Kaplan-Meier statistics and Log-rank test were 
used to study the impact of the different clinical factors 
associated with OS on univariable analysis, with 
significant variables (p<0.05) being further tested on a 
multivariable stepwise backward Cox regression model. 
We used Harrell’s rms packages to identify a subset of 
predictors by backward elimination [20], estimating 
the confidence intervals of the c-index statistics via 
bootstrapping (150 iterations). The proportional hazards 
assumption was tested by including the variable of 
interest and the product of the time varying variable 
constructed from the variable of interest in the Cox 
regression model. A resulting p>0.05 confirmed that 
the proportional hazards assumption over time was 
satisfied. The receiver operating characteristic (ROC) 
curve method was used to compare the discriminative 
ability of candidate variables in predicting 1 and 2-year 
mortality, with the area under the ROC curve (AUROC) 
being used to rank the prognostic models based on their 
predictive accuracy. Statistical analyses were performed 
using SPSS package version 11.5 5 (SPSS Inc., Chicago, 
IL, USA). R statistical package was used for c-index 
analysis [21].
ACKNOWLEDGMENTS
This work was presented orally at EASL 2015 
International Liver Meeting and awarded a Young 
Investigator Award to DJP.
FUNDING
No specific funding was obtained to support the 
conduction of this study.
CONFLICTS OF INTEREST
The authors have no conflicts of interest to disclose.
Authors contribution
Study concept and design: DJP, RS.
Acquisition of data: DJP, TA, PIS, JWJ, CS, GG, YWK, 
MK, MP, MP, PT.
Analysis and interpretation of data: DJP, EA, MP, RS.
Drafting of the manuscript: DJP, EA, RS.
Critical revision of the manuscript for important 
intellectual content: DJP, TA, EA, JWJ, CS, YWK, MK, 
PIS, MP, RS.
Statistical analysis: DJP, EA, MP.
Administrative, technical, or material support: MP, MK, 
JWJ.
Study supervision: DJP, JWJ, MK, MP, RS.
REFERENCES
1. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular 
carcinoma: the BCLC staging classification. Semin Liver 
Dis. 1999; 19:329-338.
2. Farinati F, Vanin V, Giacomin A, Pozzan C, Cillo U, 
Vitale A, Nolfo AM, Poggio PD, Benvegnu L, Rapaccini 
G, Zoli M, Borzio F, Giannini EG, Caturelli E, Trevisani 
F and The Italian Liver Cancer g. BCLC-B hepatocellular 
carcinoma and transcatheter arterial chemoembolization: 
a 20-year survey by the Italian Liver Cancer group. Liver 
Int. 2014.
3. Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of 
intermediate-stage hepatocellular carcinoma. Nat Rev Clin 
Oncol. 2014.
4. Guo Z, Zhong JH, Jiang JH, Zhang J, Xiang BD, Li LQ. 
Comparison of Survival of Patients with BCLC Stage A 
Hepatocellular Carcinoma After Hepatic Resection or 
Transarterial Chemoembolization: A Propensity Score-
Based Analysis. Ann Surg Oncol. 2014; 21:3069-3076.
5. Zhao Y, Cai G, Zhou L, Liu L, Qi X, Bai M, Li Y, Fan D, 
Han G. Transarterial chemoembolization in hepatocellular 
carcinoma with vascular invasion or extrahepatic 
metastasis: A systematic review. Asia Pac J Clin Oncol. 
2013; 9:357-364.
6. Dufour JF, Bargellini I, De Maria N, De Simone P, Goulis 
I, Marinho RT. Intermediate hepatocellular carcinoma: 
current treatments and future perspectives. Ann Oncol. 
2013; 24 Suppl 2:ii24-29.
7. Bolondi L, Burroughs A, Dufour JF, Galle PR, Mazzaferro 
V, Piscaglia F, Raoul JL, Sangro B. Heterogeneity of 
patients with intermediate (BCLC B) Hepatocellular 
Carcinoma: proposal for a subclassification to facilitate 
treatment decisions. Semin Liver Dis. 2012; 32:348-359.
8. Heng-Jun G, Yao-Jun Z, Min-Shan C, Mei-Xian C, Jun-
Ting H, Li X, Lau WY. Rationality and effectiveness of 
Oncotarget14www.impactjournals.com/oncotarget
transarterial chemoembolization as an initial treatment for 
BCLC B stage HBV-related hepatocellular carcinoma. 
Liver Int. 2013.
9. Pinato DJ, Sharma R. An inflammation-based prognostic 
index predicts survival advantage after transarterial 
chemoembolization in hepatocellular carcinoma. Transl 
Res. 2012; 160:146-152.
10. Hucke F, Sieghart W, Pinter M, Graziadei I, Vogel 
W, Muller C, Heinzl H, Waneck F, Trauner M, Peck-
Radosavljevic M. The ART-strategy: Sequential assessment 
of the ART score predicts outcome of patients with 
hepatocellular carcinoma re-treated with TACE. J Hepatol. 
2013.
11. Kadalayil L, Benini R, Pallan L, O'Beirne J, Marelli 
L, Yu D, Hackshaw A, Fox R, Johnson P, Burroughs 
AK, Palmer DH, Meyer T. A simple prognostic scoring 
system for patients receiving transarterial embolisation for 
hepatocellular cancer. Ann Oncol. 2013; 24:2565-2570.
12. Sieghart W, Hucke F, Pinter M, Graziadei I, Vogel W, 
Muller C, Heinzl H, Trauner M, Peck-Radosavljevic M. 
The ART of decision making: retreatment with transarterial 
chemoembolization in patients with hepatocellular 
carcinoma. Hepatology. 2013; 57:2261-2273.
13. Hucke F, Sieghart W, Pinter M, Graziadei I, Vogel 
W, Muller C, Heinzl H, Waneck F, Trauner M, Peck-
Radosavljevic M. The ART-strategy: sequential assessment 
of the ART score predicts outcome of patients with 
hepatocellular carcinoma re-treated with TACE. J Hepatol. 
2014; 60:118-126.
14. Kudo M, Arizumi T, Ueshima K. Assessment for 
retreatment (ART) score for repeated transarterial 
chemoembolization in patients with hepatocellular 
carcinoma. Hepatology. 2014; 59:2424-2425.
15. Terzi E, Terenzi L, Venerandi L, Croci L, Renzulli M, 
Mosconi C, Allegretti G, Granito A, Golfieri R, Bolondi L, 
Piscaglia F. The ART score is not effective to select patients 
for transarterial chemoembolization retreatment in an Italian 
series. Digestive diseases. 2014; 32:711-716.
16. Leoni S, Piscaglia F, Golfieri R, Camaggi V, Vidili 
G, Pini P, Bolondi L. The impact of vascular and 
nonvascular findings on the noninvasive diagnosis of small 
hepatocellular carcinoma based on the EASL and AASLD 
criteria. Am J Gastroenterol. 2010; 105:599-609.
17. A new prognostic system for hepatocellular carcinoma: a 
retrospective study of 435 patients: the Cancer of the Liver 
Italian Program (CLIP) investigators. Hepatology. 1998; 
28:751-755.
18. Lencioni R, Llovet JM. Modified RECIST (mRECIST) 
assessment for hepatocellular carcinoma. Semin Liver Dis. 
2010; 30:52-60.
19. Jang JW, Kwon JH, You CR, Kim JD, Woo HY, Bae SH, 
Choi JY, Yoon SK, Chung KW. Risk of HBV reactivation 
according to viral status and treatment intensity in patients 
with hepatocellular carcinoma. Antivir Ther. 2011; 
16:969-977.
20. Harrell FE. (2010). rms: Regression Modeling Strategies.
21. Team RC. (2013). R: A language and environment for 
statistical computing. (Vienna, Austria: R Foundation for 
Statistical Computing).
22. Pinato DJ, Stebbing J, Ishizuka M, Khan SA, Wasan 
HS, North BV, Kubota K, Sharma R. A novel and 
validated prognostic index in hepatocellular carcinoma: 
the inflammation based index (IBI). J Hepatol. 2012; 
57:1013-1020.
23. Sangro B. [Survival benefit with intraarterial techniques in 
hepatocellular carcinoma]. Gastroenterol Hepatol. 2014; 37 
Suppl 2:95-101.
24. Hsu C, Shen YC, Cheng CC, Hu FC, Cheng AL. 
Geographic difference in survival outcome for advanced 
hepatocellular carcinoma: implications on future clinical 
trial design. Contemp Clin Trials. 2010; 31:55-61.
25. Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina 
H, Kono M, Takita M, Kitai S, Inoue T, Yada N, 
Hagiwara S, Ida H, Minami Y, Sakurai T, Nishida N, 
Kitano M, et al. Evaluation of ART Scores for Repeated 
Transarterial Chemoembolization in Japanese Patients 
with Hepatocellular Carcinoma. Oncology. 2015; 89 Suppl 
2:4-10.
26. Yang HJ, Lee JH, Lee DH, Yu SJ, Kim YJ, Yoon JH, Kim 
HC, Lee JM, Chung JW, Yi NJ, Lee KW, Suh KS, Lee HS. 
Small single-nodule hepatocellular carcinoma: comparison 
of transarterial chemoembolization, radiofrequency 
ablation, and hepatic resection by using inverse probability 
weighting. Radiology. 2014; 271:909-918.
27. Adhoute X, Penaranda G, Naude S, Raoul JL, Perrier H, 
Bayle O, Monnet O, Beaurain P, Bazin C, Pol B, Folgoc 
GL, Castellani P, Bronowicki JP, Bourliere M. Retreatment 
with TACE: The ABCR SCORE, an aid to the decision-
making process. J Hepatol. 2015; 62:855-862.
28. Kudo M, Matsui O, Izumi N, Kadoya M, Okusaka T, 
Miyayama S, Yamakado K, Tsuchiya K, Ueshima K, 
Hiraoka A, Ikeda M, Ogasawara S, Yamashita T, Minami 
T. Transarterial Chemoembolization Failure/Refractoriness: 
JSH-LCSGJ Criteria 2014 Update. Oncology. 2014; 87 
Suppl 1:22-31.
29. Pinato DJ, Arizumi T, Allara E, Jang JW, Smirne C, 
Kim YW, Kudo M, Pirisi M, Sharma R. Validation of 
the Hepatoma Arterial Embolization Prognostic Score in 
European and Asian Populations and Proposed Modification. 
Clin Gastroenterol Hepatol. 2015; 13:1204-1208.e2.
30. Takayasu K, Arii S, Kudo M, Ichida T, Matsui O, Izumi 
N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, 
Kokudo N, Makuuchi M. Superselective transarterial 
chemoembolization for hepatocellular carcinoma. 
Validation of treatment algorithm proposed by Japanese 
guidelines. J Hepatol. 2012; 56:886-892.
